1.930USDMkt Cap: 8.29M USDP/E: —Last update: 2026-05-21
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap8.29M USD
Enterprise Value-960.18K USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-7.97M USD
Revenue/Share—
Last Price1.930 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees4
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS00510M1045
Valuation
P/E (Trailing)—
P/E (Forward)-0.91
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B0.93
EPS (TTM)-3.79
EPS (Forward)-2.13
52W Range
1.82691% of range1.940
52W High1.940 USD
52W Low1.826 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-151.21%
ROA-103.60%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-6.79M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-39.67%
Net Debt-9.25M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio3.77
Quick Ratio3.69
Book Value/Sh2.069 USD
Cash/Share2.153 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:20
Split DateAug 5, 2025
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)17.00 USD
Target Range10.00 USD – 31.00 USD
# Analysts3
Ownership
Shares Out.4.30M
Float4.15M
Insiders2.99%
Institutions6.20%
Short Interest
Short Ratio0.6d
Short % Float4.23%
Short % Out.4.03%
Shares Short114.95K
Short (prev mo.)102.29K
Technical
SMA 502.990 (-35.4%)
SMA 2003.695 (-47.8%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)70.24K
Avg Vol (10d)110.33K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—